Sigma-2 antagonist
Sigma-2 receptor antagonist
- Preclinical evidence of neuroprotection through mitochondrial stability
- Theoretically beneficial for schizophrenia
- ➔ none are clinically available
- ➔ roluperidone – FDA rejected for schizophrenia (efficacy concerns)
Drugs that bind this target
- roluperidone — FDA rejected for schizophrenia
No ballicule in the library carries this peg — no selective agent is clinically available, so the binding is shown here rather than on a card.
All mechanisms · Open the interactive console ↗